Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Gene Rearrangement
  • Genome, Human
  • High-Throughput Nucleotide Sequencing
  • Lung Neoplasms

abstract

  • Broad, hybrid capture-based NGS identified actionable genomic alterations in 65% [95% confidence interval (CI), 48%-82%] of tumors from never or light smokers with lung cancers deemed without targetable genomic alterations by earlier extensive non-NGS testing. These findings support first-line profiling of lung adenocarcinomas using this approach as a more comprehensive and efficient strategy compared with non-NGS testing. See related commentary by McCutcheon and Giaccone, p. 3584.

publication date

  • August 15, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4917003

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-14-2683

PubMed ID

  • 25567908

Additional Document Info

start page

  • 3631

end page

  • 9

volume

  • 21

number

  • 16